Updating a meta analysis of intervention research with challenging behaviour dating hamilton playing cards

Posted by / 06-Mar-2020 23:00

Updating a meta analysis of intervention research with challenging behaviour

Google(); req('single_work'); $('.js-splash-single-step-signup-download-button').one('click', function(e){ req_and_ready('single_work', function() ); new c.

Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. Weight history and all-cause and cause-specific mortality in three prospective cohort studies. A meta-analysis but not a systematic review: an evaluation of the Global BMI Mortality Collaboration. Using the Edmonton obesity staging system to predict mortality in a population-representative cohort of people with overweight and obesity. uses cookies to personalize content, tailor ads and improve the user experience. By using our site, you agree to our collection of information through the use of cookies. Chronic disease management: Aim of the intervention was the management of an existing chronic disease. Excluded study design: Study did not use an included design. Literature Search Strategies for Primary Literaturee Methods. Quality Assessment Criteria for Randomized Clinical Trialse Table 1. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. doi:10.1001/jama.295.6.676Pub Med Google Scholar Crossref Acharya NV, Wilton LV, Shakir SA. doi:10.1038/0803323Pub Med Google Scholar Crossref Ackermann RT, Finch EA, Brizendine E, Zhou H, Marrero DG. doi:10.1016/j.amepre.20Pub Med Google Scholar Crossref Ackermann RT, Liss DT, Finch EA, et al. doi:10.2105/AJPH.2015.302641Pub Med Google Scholar Crossref Allison DB, Gadde KM, Garvey WT, et al. doi:10.1038/oby.2011.330Pub Med Google Scholar Crossref Anderson AS, Craigie AM, Caswell S, et al. doi:10.1136/bmj.g1823Pub Med Google Scholar Crossref Apovian CM, Aronne L, Rubino D, et al; COR-II Study Group. doi:10.1002/oby.20309Pub Med Google Scholar Crossref Appel LJ, Clark JM, Yeh HC, et al. doi:10.1056/NEJMoa1108660Pub Med Google Scholar Crossref Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. doi:10.1002/oby.20584Pub Med Google Scholar Crossref Astrup A, Carraro R, Finer N, et al; NN8022-1807 Investigators. doi:10.1038/ijo.2011.158Pub Med Google Scholar Crossref Aveyard P, Lewis A, Tearne S, et al. doi:10.1016/S0140-6736(16)31893-1Pub Med Google Scholar Crossref Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I; Orlistat and Resistant Hypertension Investigators. doi:10.1097/00004872-200211000-00026Pub Med Google Scholar Crossref Befort CA, Klemp JR, Sullivan DK, et al. doi:10.1002/oby.21625Pub Med Google Scholar Crossref Bennett GG, Warner ET, Glasgow RE, et al; Be Fit, Be Well Study Investigators. doi:10.1001/archinternmed.2012.1Pub Med Google Scholar Crossref Bhopal RS, Douglas A, Wallia S, et al. doi:10.1016/S2213-8587(13)70204-3Pub Med Google Scholar Crossref Broom I, Hughes E, Dodson P, Reckless J. Google Scholar Broom I, Wilding J, Stott P, Myers N; UK Multimorbidity Study Group. Pub Med Google Scholar Burke V, Beilin LJ, Cutt HE, Mansour J, Wilson A, Mori TA. doi:10.1097/010000170388.61579.4f Pub Med Google Scholar Crossref Cadmus-Bertram L, Nelson SH, Hartman S, Patterson RE, Parker BA, Pierce JP. doi:10.1007/s10865-016-9735-9Pub Med Google Scholar Crossref Chirinos DA, Goldberg RB, Llabre MM, et al. doi:10.1007/s10865-016-9721-2Pub Med Google Scholar Crossref Christian JG, Byers TE, Christian KK, et al. doi:10.1016/20Pub Med Google Scholar Crossref Cussler EC, Teixeira PJ, Going SB, et al. doi:10.1038/oby.2008.19Pub Med Google Scholar Crossref Davidson MH, Hauptman J, Di Girolamo M, et al. doi:10.1001/jama.281.3.235Pub Med Google Scholar Crossrefde Vos BC, Runhaar J, Bierma-Zeinstra SM. doi:10.1007/s00394-013-0505-y Pub Med Google Scholar Crossref Demark-Wahnefried W, Jones LW, Snyder DC, et al. doi:10.1002/cncr.28761Pub Med Google Scholar Crossref Derosa G, Mugellini A, Ciccarelli L, Fogari R. doi:10.1016/S0149-2918(03)80070-XPub Med Google Scholar Crossref Eaton CB, Hartman SJ, Perzanowski E, et al. doi:10.1370/afm.1952Pub Med Google Scholar Crossref Farr OM, Upadhyay J, Gavrieli A, et al. doi:10.2337/db16-0635Pub Med Google Scholar Crossref Fidler MC, Sanchez M, Raether B, et al; BLOSSOM Clinical Trial Group. doi:10.1210/jc.2011-1256Pub Med Google Scholar Crossref Finer N, James WP, Kopelman PG, Lean ME, Williams G. doi:10.1038/0801128Pub Med Google Scholar Crossref Fitzgibbon ML, Stolley MR, Schiffer L, Sharp LK, Singh V, Dyer A. doi:10.1038/oby.2010.47Pub Med Google Scholar Crossref Gadde KM, Allison DB, Ryan DH, et al. Using social and mobile tools for weight loss in overweight and obese young adults (Project SMART): a 2 year, parallel-group, randomised, controlled trial. Waste the waist: a pilot randomised controlled trial of a primary care based intervention to support lifestyle change in people with high cardiovascular risk. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [published corrections appear in Lancet. Characteristics of All Randomized Clinical Trials, by Intervention Type and Author (k=124)e Table 2. Comparison of two methods to detect publication bias in meta-analysis. Safety profile of orlistat: results of a prescription-event monitoring study. Translating the diabetes prevention program into the community: the DEPLOY pilot study. A randomized comparative effectiveness trial for preventing type 2 diabetes. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). The impact of a bodyweight and physical activity intervention (Be WEL) initiated through a national colorectal cancer screening programme: randomised controlled trial. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Comparative effectiveness of weight-loss interventions in clinical practice. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Screening and brief intervention for obesity in primary care: a parallel, two-arm, randomised trial. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. Weight loss maintenance strategies among rural breast cancer survivors: the rural women connecting for better health trial. Obesity treatment for socioeconomically disadvantaged patients in primary care practice. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family-cluster randomised controlled trial. The role of orlistat in the treatment of obese patients with mild to moderate hypercholesterolaemia: consequences for coronary risk. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. Effects of a lifestyle programme on ambulatory blood pressure and drug dosage in treated hypertensive patients: a randomized controlled trial. Randomized trial of a phone- and web-based weight loss program for women at elevated breast cancer risk: the HELP study. Lifestyle modification and weight reduction among low-income patients with the metabolic syndrome: the CHARMS randomized controlled trial. A computer support program that helps clinicians provide patients with metabolic syndrome tailored counseling to promote weight loss. Maintenance of weight loss in overweight middle-aged women through the Internet. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. Effectiveness of a tailor-made weight loss intervention in primary care. Daughters and Mothers Against Breast Cancer (DAMES): main outcomes of a randomized controlled trial of weight loss in overweight mothers with breast cancer and their overweight daughters. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both on anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. A randomized clinical trial of a tailored lifestyle intervention for obese, sedentary, primary care patients. Lorcaserin administration decreases activation of brain centers in response to food cues and these emotion- and salience-related changes correlate with weight loss effects: a 4-week-long randomized, placebo-controlled, double-blind clinical trial. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Obesity Reduction Black Intervention Trial (ORBIT): 18-month results. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial [published correction appears in Lancet.

updating a meta analysis of intervention research with challenging behaviour-83updating a meta analysis of intervention research with challenging behaviour-4updating a meta analysis of intervention research with challenging behaviour-2

Method: Four effect-size algorithms were calculated for published intervention cases, and results analysed and compared to previous findings by behaviour target, intervention type, and other factors.

One thought on “updating a meta analysis of intervention research with challenging behaviour”